Cardiomyocyte apoptosis in hypertensive cardiomyopathy

Cardiovascular Research

Volumn 59, Issue 3, 2003, Pages 549-562

  González, Arantxa ^a   Fortuño, María A ^a   Querejeta, Ramón ^b   Ravassa, Susana ^a   López, Begoña ^a   López, Natalia ^a   Díez, Javier ^a,c  

^a UNIVERSITY OF NAVARRA   (Spain)

^b HOSPITAL DONOSTIA   (Spain)

^c UNIVERSITY CLINIC OF NAVARRA   (Spain)

Author keywords

Apoptosis; Arterial hypertension; Cardiomyocytes; Heart failure

Indexed keywords

ANTIHYPERTENSIVE AGENT; ANTIOXIDANT; APOPTOSIS SIGNAL REGULATING KINASE 1; APOPTOTIC PROTEASE ACTIVATING FACTOR 1; BIOLOGICAL FACTOR; CARVEDILOL; CASPASE 3; CASPASE 8; CASPASE 9; DAXX PROTEIN; ENDOTHELIN 1; FAS ANTIBODY; FAS LIGAND; FLICE INHIBITORY PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LIGAND; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE P38; PROPRANOLOL; PROTEIN BCL 2; PROTEIN DERIVATIVE; PROTEIN KINASE B; STRESS ACTIVATED PROTEIN KINASE; TUMOR NECROSIS FACTOR RECEPTOR; TUMOR NECROSIS FACTOR RECEPTOR 2;

APOPTOSIS; CELL ACTIVITY; CELL COUNT; CELL DEATH; CELL DIFFERENTIATION; CELL STIMULATION; CELL SURVIVAL; DNA DEGRADATION; DRUG EFFECT; DRUG EFFICACY; DRUG POTENCY; ENERGY YIELD; ENZYME ACTIVITY; ENZYME RELEASE; EXPERIMENTAL TEST; HEART CONTRACTION; HEART DISEASE; HEART FUNCTION; HEART MUSCLE CELL; HUMAN; HYPERTENSION; LIGAND BINDING; MOLECULAR MECHANICS; NONHUMAN; PATHOGENESIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN DEGRADATION; PROTEIN DOMAIN; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION;

ANGIOTENSIN II; ANIMALS; ANTIHYPERTENSIVE AGENTS; ANTIOXIDANTS; APOPTOSIS; ARRHYTHMIA; HUMANS; HYPERTENSION; MAP KINASE SIGNALING SYSTEM; MODELS, ANIMAL; MYOCARDIAL ISCHEMIA; MYOCYTES, CARDIAC; OXIDATIVE STRESS; VENTRICULAR REMODELING;

EID: 1642379736     PISSN: 00086363     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0008-6363(03)00498-X     Document Type: Review

References (180)

1. Kanduc D., Mittelman A., Serpico R., et al. Cell death: apoptosis versus necrosis. Int J Oncol. 21:2002;165-170.
2. Clerk P.G.H. Developmental cell death: morphological diversity and multiple mechanisms. Anat Embryol. 181:1990;195-213.
3. Majno G., Joris I. Apoptosis, oncosis, and necrosis: an overview of cell death. Am J Pathol. 146:1995;3-15.
4. Ashkenazi A., Dixit V.M. Death receptors: signaling and modulation. Science. 281:1998;1305-1308.
5. Hengartner M.O. The biochemistry of apoptosis. Nature. 407:2000;770-776.
6. Kroemer G., Reed J.C. Mitochondrial control of cell death. Nature Med. 6:2000;513-519.
7. Ferri K.F., Kroemer G. Organelle-specific initiation of cell death pathways. Nat Cell Biol. 3:2001;E255-E263.
8. Adams J.M., Cory S. The Bcl-2 protein family: arbiters of cell survival. Science. 281:1998;1322-1326.
9. Goya L. Cell death inhibition: keeping caspases in check. Cell. 104:2001;805-808.
10. Grütter M.G. Caspases: key players in programmed cell death. Curr Opin Cell Biol. 10:2000;649-655.
11. Turk B., Turk D., Turk V. Lysosomal cysteine proteases: more than scavengers. Biochim Biophys Acta. 1477:2000;98-111.
12. Huang Y., Wang K.K.W. The calpain family and human disease. Trends Mol Med. 7:2001;355-362.
13. Xia Z., Dickens M., Raingeaud J., Davis R.J., Greenberg M.E. Opposing effects of ERK, and JNK-p38 MAP kinases on apoptosis. Science. 270:1995;1326-1331.
14. Li X., Stark G.R. NFKappaB-dependent signaling pathways. Exp Hematol. 30:2002;285-296.
15. Neri L.M., Borgatti P., Capitani S., Martelli A.M. The nuclear phosphoinositide 3-kinase/AKT pathway: a new second messenger system. Biochim Biophys Acta. 1584:2002;73-80.
16. Wang Z. The expanding role of mitochondria in apoptosis. Genes Dev. 15:2001;2922-2933.
17. Du C., Fang M., Li Y., Li L., Wang X. Smac, a mitochondrial protein that promotes cytochrome c-dependent caspase activation by eliminating IAP inhibition. Cell. 102:2000;33-42.
18. Gupta S. Molecular signaling in death receptor and mitochondrial pathways of apoptosis. Int J Oncol. 22:2003;15-20.
19. Luo X., Budihardjo I., Zou H., Slaughter C., Wang X. Bid, a Bcl-2 interacting protein, mediates cytochrome c release from mitochondria in response to activation of cell surface death receptors. Cell. 94:1998;481-490.
20. Li H., Zhu H., Xu C.J., Yuan J. Cleavage of Bid by caspase-8 mediates the mitochondrial damage in the Fas pathway of apoptosis. Cell. 94:1998;491-501.
21. Matsuzawa A., Ichijo H. Molecular mechanisms of the decision between life and death: regulation of apoptosis by apoptosis signal-regulating kinase 1. J Biochem. 130:2001;1-8.
22. Adams J.M., Cory S. Life-or-death decisions by the Bcl-2 protein family. Trends Biochem Sci. 26:2001;61-66.
23. Antonsson B. Bax and other pro-apoptotic Bcl-2 family 'killer-proteins' and their victim the mitochondrion. Cell Tissue Res. 306:2001;347-361.
24. Bishopric N.H., Andreka P., Slepak T., Webster K.A. Molecular mechanisms of apoptosis in the cardiac myocyte. Curr Opin Pharmacol. 1:2001;141-150.
25. Nakamura T., Ueda Y., Juan Y., et al. Fas-mediated apoptosis in adriamycin-induced cardiomyopathy in rats: in vivo study. Circulation. 102:2000;572-578.
26. Krown K.A., Page M.T., Nguyen C., et al. Tumor necrosis factor alpha-induced apoptosis in cardiac myocytes. Involvement of the sphingolipid signaling cascade in cardiac cell death. J Clin Invest. 98:1996;2854-2865.
27. Leri A., Fiordaliso F., Setoguchi M., et al. Inhibition of p53 function prevents renin-angiotensin system activation and stretch mediated myocyte apoptosis. Am J Pathol. 157:2000;843-857.
28. Azhar G., Liu L., Zhang X., Wei J.Y. Influence of age on hypoxia/reoxygenation-induced DNA fragmentation and bcl-2, bcl-xl, bax and fas in the rat heart and brain. Mech Ageing Dev. 112:1999;5-25.
29. Ing D.J., Zang J., Dzau V.J., Webster K.A., Bishopric N.H. Modulation of cytokine-induced cardiac myocyte apoptosis by nitric oxide, Bak and Bcl-x. Circ Res. 84:1999;21-33.
30. Cook S.A., Sugden P.H., Clerk A. Regulation of bcl-2 family proteins during development and in response to oxidative stress in cardiac myocytes: association with changes in mitochondrial membrane potential. Circ Res. 85:1999;940-949.
31. Bialik S., Cryns V.L., Drincic A., et al. The mitochondrial apoptotic pathway is activated by serum and glucose deprivation in cardiac myocytes. Circ Res. 85:1999;403-414.
32. de Moissac D., Gurevich R.M., Zheng H., Singal P.K., Kirshenbaum L.A. Caspase activation and mitochondrial cytochrome c release during hypoxia-mediated apoptosis of adult ventricular myocytes. J Mol Cell Cardiol. 32:2000;53-63.
33. q signaling is mediated by permeability transition pore formation and activation of the mitochondrial death pathway. Circ Res. 87:2000;1180-1187.
34. Aoki H., Kang P.M., Hampe J., et al. Direct activation of mitochondrial apoptosis machinery by c-Jun N-terminal kinase in adult cardiac myocytes. J Biol Chem. 277:2002;10244-10250.
35. Laderoute K.R., Webster K.A. Hypoxia/reoxygenation stimulates Jun kinase activity through redox signaling in cardiac myocytes. Circ Res. 80:1997;336-344.
36. Ma X.L., Kumar S., Gao F., et al. Inhibition of p38 mitogen-activated protein kinase decreases cardiomyocyte apoptosis and improves cardiac function after myocardial ischemia and reperfusion. Circulation. 99:1999;1685-1691.
37. Cook S.A., Sugden P.H., Clerk A. Activation of c-Jun N-terminal kinases and p38-mitogen-activated protein kinases in human heart failure secondary to ischaemic heart disease. J Mol Cell Cardiol. 31:1999;1429-1434.
38. Li Q., Li B., Wang X., et al. Overexpression of insulin-like growth factor-1 in mice protects from myocyte death after infarction, attenuating ventricular dilation, wall stress, and cardiac hypertrophy. J Clin Invest. 100:1997;1991-1999.
39. Kuwahara K., Saito Y., Kishimoto I., et al. Cardiotrophin-1 phosphorylates Akt and BAD, and prolongs cell survival via a PI3K-dependent pathway in cardiac myocytes. J Mol Cell Cardiol. 32:2000;1385-1391.
40. Imanishi T., Murry C.E., Reinecke H., et al. Cellular FLIP is expressed in cardiomyocytes and down-regulated in TUNEL-positive grafted cardiac tissues. Cardiovasc Res. 48:2000;101-110.
41. Scheubel R.J., Bartling B., Simm A., et al. Apoptotic pathway activation from mitochondria and death receptors without caspase-3 cleavage in failing human myocardium: fragile balance of myocyte survival? J Am Coll Cardiol. 39:2002;481-488.
42. Nelson D.P., Setser E., Hall D.G., et al. Proinflammatory consequences of transgenic Fas ligand expression in the heart. J Clin Invest. 105:2000;1199-1208.
43. Jeremias I., Kupatt C., Martín-Villalba A., et al. Involvement of CD95/Apo 1/Fas in cell death after myocardial ischemia. Circulation. 102:2000;915-920.
44. Clerk A., Cole S.M., Cullingford T.E., et al. Regulation of cardiac myocyte cell death. Pharmacol Ther. 97:2003;223-261.
45. Reed J.C., Paternostro G. Postmitochondrial regulation of apoptosis during heart failure. Proc Natl Acad Sci USA. 996:1999;7614-7616.
46. Los M., Mozoluk M., Ferrari D., et al. Activation and caspase-mediated inhibition of PARP: a molecular switch between fibroblast necrosis and apoptosis in death receptor asignaling. Mol Biol Cell. 13:2002;978-988.
47. Narula J., Pandey P., Arbustini E., et al. Apoptosis in heart failure: release of cytochrome c from mitochondria and activation of caspase-3 in human cardiomyopathy. Proc Natl Acad Sci USA. 96:1999;8144-8149.
48. Narula J., Arbustini E., Chandrashekhar Y., Schwaiger M. Apoptosis and systolic dysfunction in heart failure. Story of apoptosis interruptus and zombie myocytes. Cardiol Clin. 19:2001;113-126.
49. Haider N., Narula N., Narula J. Apoptosis in heart failure represents programmed cell survival, not death, of cardiomyocytes and likelihood of reverse remodeling. J Card Fail. 8:2002;S512-S517.
50. James T.N., St Martin E., Willis P.W. 3rd, Lohr T.O. Apoptosis as a possible cause of gradual development of complete heart block and fatal arrhythmias associated with absence of the AV node, sinus node, and internodal pathways. Circulation. 93:1996;1424-1438.
51. James T.N. Normal and abnormal consequences of apoptosis in the human heart. From postnatal morphogenesis to paroxysmal arrhythmias. Circulation. 90:1994;556-573.
52. Bardales R.H., Hailey L.S., Xie S.S., Schaefer R.F., Hsu S.M. In situ apoptosis assay for the detection of early acute myocardial infarction. Am J Pathol. 149:1996;821-829.
53. Hofstra L., Liem I.H., Dumont E.A., et al. Visualisation of cell death in vivo in patients with acute myocardial infarction. Lancet. 356:2000;209-212.
54. Olivetti G., Quaini F., Sala R., et al. Acute myocardial infarction in humans is associated with activation of programmed myocyte cell death in the surviving portion of the heart. J Mol Cell Cardiol. 28:1996;2005-2016.
55. Saraste A., Pulkki K., Kallajoki M., et al. Apoptosis in human acute myocardial infarction. Circulation. 95:1997;320-323.
56. Baldi A., Abbate A., Bussani R., et al. Apoptosis and post-infarction left ventricular remodeling. J Mol Cell Cardiol. 34:2002;165-174.
57. Narula J., Acio E.R., Narula N., et al. Annexin-V imaging for noninvasive detection of cardiac allograft rejection. Nat Med. 7:2001;1347-1352.
58. Panizo-Santos A., Lozano M.D., Distefano S., Inoges S., Pardo J. Clinico-pathologic, immunohistochemical, and TUNEL study in early cardiac allograft failure. Cardiovasc Pathol. 9:2000;153-159.
59. Puig M., Ballester M., Matias-Guiu X., et al. Burden of myocardial damage in cardiac allograft rejection: scintigraphic evidence of myocardial injury and histologic evidence of myocyte necrosis and apoptosis. J Nucl Cardiol. 7:2000;132-139.
60. Guerra S., Leri A., Wang X., et al. Myocyte death in the failing human heart is gender dependent. Circ Res. 85:1999;856-866.
61. Latif N., Khan M.A., Birks E., et al. Upregulation of the Bcl-2 family of proteins in end stage heart failure. J Am Coll Cardiol. 35:2000;1769-1777.
62. Narula J., Haider N., Virmani R., et al. Apoptosis in myocytes in end-stage heart failure. New Engl J Med. 335:1996;1182-1189.
63. Olivetti G., Abbi R., Quaini F., et al. Apoptosis in the failing human heart. New Engl J Med. 336:1997;1131-1141.
64. Rayment N.B., Haven A.J., Madden B., et al. Myocyte loss in chronic heart failure. J Pathol. 188:1999;213-219.
65. Saraste A., Pulkki K., Kallajoki M., et al. Cardiomyocyte apoptosis and progression of heart failure to transplantation. Eur J Clin Invest. 29:1999;380-386.
66. Yao M., Keogh A., Spratt P., dos Remedios C.G., Kiessling P.C. Elevated DNase I levels in human idiopathic dilated cardiomyopathy: an indicator of apoptosis? J Mol Cell Cardiol. 28:1996;95-101.
67. Kostin S., Pool L., Elsasser A., et al. Myocytes die by multiple mechanisms in failing human hearts. Circ Res. 92:2003;715-724.
68. Kavantzas N.G., Lazaris A.C., Agapitos E.V., Nanas J., Davaris P.S. Histological assessment of apoptotic cell death in cardiomyopathies. Pathology. 32:2000;176-180.
69. Frustaci A., Chimenti C., Setoguchi M., et al. Cell death in acromegalic cardiomyopathy. Circulation. 99:1999;1426-1434.
70. Frustaci A., Kajstura J., Chimenti C., et al. Myocardial cell death in human diabetes. Circ Res. 87:2000;1123-1132.
71. Mallat Z., Tedgui A., Fontaliran F., et al. Evidence of apoptosis in arrhythmogenic right ventricular dysplasia. New Engl J Med. 335:1996;1190-1196.
72. Valente M., Calabrese F., Thiene G., et al. In vivo evidence of apoptosis in arrhythmogenic right ventricular cardiomyopathy. Am J Pathol. 152:1998;479-484.
73. Toyozaki T., Hiroe M., Tanaka M., et al. Levels of soluble Fas ligand in myocarditis. Am J Cardiol. 82:1998;246-248.
74. Ino T., Nishimoto K., Okubo M., et al. Apoptosis as a possible cause of wall thinning in end-stage hypertrophic cardiomyopathy. Am J Cardiol. 79:1997;1137-1141.
75. Freude B., Masters T.N., Kostin S., Robicsek F., Schaper J. Cardiomyocyte apoptosis in acute and chronic conditions. Basic Res Cardiol. 93:1998;85-89.
76. Haunstetter A., Izumo S. Apoptosis: basic mechanisms and implications for cardiovascular disease. Circ Res. 82:1998;1111-1129.
77. James T.N. Apoptosis in cardiac disease. Am J Med. 107:1999;606-620.
78. Neuss M., Crow M.T., Chesley A., Lakatta E.G. Apoptosis in cardiac disease - what is it - how does it occur. Cardiovasc Drugs Ther. 15:2001;507-523.
79. Kang P.M., Izumo S. Apoptosis in heart: basic mechanisms and implications in cardiovascular diseases. Trends Mol Med. 9:2003;177-182.
80. Díez J., Panizo A., Hernández M., et al. Cardiomyocyte apoptosis and cardiac angiotensin-converting enzyme in spontaneously hypertensive rats. Hypertension. 30:1997;1029-1034.
81. Hamet P., Richard L., Dam T.V., et al. Apoptosis in target organs in hypertension. Hypertension. 26:1995;642-648.
82. Li Z., Bing O.H., Long X., Robinson K.G., Lakatta E.G. Increased cardiomyocyte apoptosis during the transition to heart failure in the spontaneously hypertensive rat. Am J Physiol. 272:1997;H2313-H2319.
83. Liu J.J., Peng L., Bradley C.J., et al. Increased apoptosis in the heart of genetic hypertension, associated with increased fibroblasts. Cardiovasc Res. 45:2000;729-735.
84. Li P., Zhang X., Capasso J.M., et al. Myocyte loss and left ventricular failure characterize the long term effects of coronary artery narrowing or renal hypertension in rats. Cardiovasc Res. 27:1993;1066-1075.
85. Diep Q.N., El Mabrouk M., Yue P., Schiffrin E.L. Effect of AT(1) receptor blockade on cardiac apoptosis in angiotensin II-induced hypertension. Am J Physiol. 282:2002;H1635-H1641.
86. Ikeda S., Hamada M., Qu P., et al. Relationship between cardiomyocyte cell death and cardiac function during hypertensive cardiac remodelling in Dahl rats. Clin Sci. 102:2002;329-335.
87. Mirsky I., Pfeffer J.M., Pfeffer M.A., Braunwald E. The contractile state as a major determinant in the evolution of left ventricular dysfunction in the spontaneously hypertensive rat. Circ Res. 53:1983;767-778.
88. Pfeffer J.M., Pfeffer M.A., Fishbein M.C., Frohlich E.D. Cardiac hypertensive rat. Am J Physiol. 237:1979;H461-H468.
89. Conrad C.H., Brooks W.W., Hayes J.A., et al. Myocardial fibrosis and stiffness with hypertrophy and heart failure in the spontaneously hypertensive rat. Circulation. 91:1995;161-170.
90. González A., López B., Ravassa S., et al. Stimulation of cardiac apoptosis in essential hypertension: potential role of angiotensin II. Hypertension. 39:2002;75-80.
91. Yamamoto S., Sawada K., Shimomura H., Kawamura K., James T.N. On the nature of cell death during remodeling of hypertrophied human myocardium. J Mol Cell Cardiol. 32:2000;161-175.
92. González A, Ravassa S, López B et al. Apoptosis in the failing hypertensive human heart (unpublished data).
93. Olivetti G., Melissari M., Balbi T., et al. Myocyte cellular hypertrophy is responsible for ventricular remodelling in the hypertrophied heart of middle aged individuals in the absence of cardiac failure. Cardiovasc Res. 28:1994;1199-1208.
94. Olivetti G., Melissari M., Balbi T., et al. Myocyte nuclear and possible cellular hyperplasia contribute to ventricular remodeling in the hypertrophic senescent heart in humans. J Am Coll Cardiol. 24:1994;140-149.
95. Anversa P., Olivetti G., Leri A., Liu Y., Kajstura J. Myocyte death and ventricular remodeling. Curr Opin Nephrol Hypertens. 6:1997;169-176.
96. Fortuño M.A., Ravassa S., Fortuño A., Zalba G., Díez J. Cardiomyocyte apoptotic cell death in arterial hypertension. Mechanisms and potential management. Hypertension. 38:2001;1406-1412.
97. Teiger E., Than V.D., Richard L., et al. Apoptosis in pressure overload-induced heart hypertrophy in the rat. J Clin Invest. 97:1996;2891-2897.
98. Cheng W., Li B., Kajstura J., et al. Stretch-induced programmed myocyte cell death. J Clin Invest. 96:1995;2247-2259.
99. Leri A., Claudio P.P., Li Q., et al. Stretch-mediated release of angiotensin II induces myocyte apoptosis by activating p53 that enhances the local renin-angiotensin system and decreases the Bcl-2-to-Bax protein ratio in the cell. J Clin Invest. 101:1998;1326-1342.
100. Sadoshima J., Izumo S. The cellular and molecular response of cardiac myocytes to mechanical stress. Annu Rev Physiol. 59:1997;551-571.
101. Fortuño M.A., Ravassa S., Etayo J.C., Díez J. Overexpression of Bax protein and enhanced apoptosis in the left ventricle of spontaneously hypertensive rats: effects of AT1 blockade with losartan. Hypertension. 32:1998;280-286.
102. Fortuño M.A., Zalba G., Ravassa S., et al. p53-Mediated upregulation of BAX gene transcription is not involved in Bax-α protein overexpression in the left ventricle of spontaneously hypertensive rats. Hypertension. 30:1999;1348-1352.
103. Hein S., Arnon E., Kostin S., et al. Progression from compensated hypertrophy to failure in the pressure-overloaded human heart: structural deterioration and compensatory mechanisms. Circulation. 107:2003;984-991.
104. Sharov V.G., Todor A., Suzuki G., et al. Hypoxia, angiotensin-II, and norepinephrine mediated apoptosis is stimulus specific in canine failed cardiomyocytes: a role for p38 MAPK, Fas-L and cyclin D(1). Eur J Heart Fail. 5:2003;121-129.
105. Cigola E., Kajstura J., Li B., Meggs L.G., Anversa P. Angiotensin II activates programmed myocyte cell death in vitro. Exp Cell Res. 231:1997;363-371.
106. Kajstura J., Cheng W., Sarangarajan R., et al. Necrotic and apoptotic myocyte cell death in the aging heart of Fischer 344 rats. Am J Physiol. 271:1996;H1215-H1228.
107. Ravassa S., Fortuño M.A., González A., et al. Mechanisms of increased susceptibility to angiotensin II-induced apoptosis in ventricular cardiomyocytes of spontaneously hypertensive rats. Hypertension. 36:2000;1065-1071.
108. Matsubara H. Pathophysiological role of angiotensin II type 2 receptor in cardiovascular and renal diseases. Circ Res. 83:1998;1182-1191.
109. Sugino H., Ozono R., Kurisu S., et al. Apoptosis is not increased in myocardium overexpressing type 2 angiotensin II receptor in transgenic mice. Hypertension. 37:2001;1394-1398.
110. De Angelis N., Fiordaliso F., Latini R., et al. Appraisal of the role of angiotensin II and aldosterone in ventricular myocyte apoptosis in adult normotensive rat. J Mol Cell Cardiol. 34:2002;1655-1665.
111. Chandrashekhar Y., Narula J. Death hath a thousand doors to let out life. Circ Res. 92:2003;710-714.
112. Chien K. Stress pathways in heart failure. Cell. 98:1999;555-558.
113. Latchman D.S. Cardiotrophin-1 (CT-1): a novel hypertrophic and cardioprotective agent. Int J Exp Pathol. 80:1999;189-196.
114. Hunter J., Chien K.R. Signaling pathways for cardiac hypertrophy and failure. New Engl J Med. 341:1999;1276-1283.
115. Sam F., Samyer D.B., Chang D.L., et al. Progressive left ventricular remodeling and apoptosis late after myocardial infarction in mouse heart. Am J Physiol. 279:2000;H422-H428.
116. Ravassa S., Ardanáz N., López B., et al. Involvement of cardiotrophin-1 signaling pathway in cardiac apoptosis of spontaneously hypertensive rats. J Hypertens. 20:(suppl 4):2002;S30. abstract.
117. Depre C., Taegtmeyer H. Metabolic aspects of programmed cell survival and cell death in the heart. Cardiovasc Res. 45:2000;538-548.
118. Frohlich E.D. Fibrosis and ischemia: the real risks in hypertensive heart disease. Am J Hypertens. 14:2001;194S-199S.
119. Phillips R.A., Diamomd J.A. Left ventricular hypertrophy, congestive heart failure, and coronary flow reserve abnormalities in hypertension. Oparil S., Weber M.A. Hypertension. 2000;244-277 WB Saunders, Philadelphia.
120. Wagoner L.E., Walsh R.A. The cellular pathophysiology of progression to heart failure. Curr Opin Cardiol. 11:1996;237-244.
121. Weber K.T. Extracellular matrix remodeling in heart failure. A role for de novo angiotensin II generation. Circulation. 96:1997;4065-4082.
122. Bing O.H.L. Hypothesis. Apoptosis may be a mechanism for the transition to heart failure with chronic pressure overload. J Mol Cell Cardiol. 26:1994;943-948.
123. Narula J., Kolodgie F.D., Virmani R. Apoptosis and cardiomyopathy. Curr Opin Cardiol. 15:2000;183-188.
124. Díez J., Fortuño M.A., Ravassa S. Apoptosis in hypertensive heart disease. Curr Opin Cardiol. 13:1998;317-325.
125. Fortuño M.A., González A., Ravassa S., López B., Díez J. Clinical implications of apoptosis in hypertensive heart disease. Am J Heart Circ Physiol. 284:2003;H1495-H1506.
126. Francis G.S., Anwar F., Bank A.J., Kubo S.H., Jessurun J. Apoptosis, Bcl-2, and proliferating cell nuclear antigen in the failing human heart: observations made after implantation of left ventricular assist device. J Card Fail. 5:1999;308-315.
127. Petrovic D., Zorc-Pleskovic R., Zorc M. Apoptosis and proliferation of cardiomyocytes in heart failure of different etiologies. Cardiovasc Pathol. 9:2000;149-152.
128. Kajstura J., Leri A., Finato N., et al. Myocyte proliferation in end-stage cardiac failure in humans. Proc Natl Acad Sci USA. 95:1998;8801-8805.
129. Beltrami A.P., Urbanek K., Kajstura J., et al. Evidence that human cardiac myocytes divide after myocardial infarction. New Engl J Med. 344:2001;1750-1757.
130. Quainin F., Urbanek K., Beltrami A.P., et al. Chimerism of the transplanted heart. New Engl J Med. 346:2002;5-15.
131. Nadal-Ginard B., Kajstura J., Leri A., Anversa P. Myocyte death, growth, and regeneration in cardiac hypertrophy and failure. Circ Res. 92:2003;139-150.
132. Colucci W.S., Braunwald E. Pathophysiology of heart failure. Braunwald E., Zippes D.P., Libby P. Heart disease. 6th ed. 2001;503-533 WB Saunders, Philadelphia.
133. Communal C., Sumandea M., de Tombe P., et al. Functional consequences of caspase activation in cardiac myocytes. Proc Natl Acad Sci USA. 99:2002;6252-6256.
134. Laugwitz K.L., Moretti A., Weig H.J., et al. Blocking caspase-activated apoptosis improves contractility in failing myocardium. Hum Gene Ther. 12:2001;2051-2063.
135. Sharov V.G., Sabbah H.N., Cook J.M., et al. Abnormal mitochondrial respiration in failed human and dog myocardium. J Mol Cell Cardiol. 30:1998;1757-1762.
136. 31P-SLOOP magnetic resonance spectroscopy. J Am Coll Cardiol. 40:2002;1267-1274.
137. Díez J., López B., González A., Querejeta R. Clinical aspects of hypertensive myocardial fibrosis. Curr Opin Cardiol. 16:2001;328-335.
138. Brilla C.G., Matsubara L., Weber K.T. Advanced hypertensive heart disease in spontaneously hypertensive rats. Lisinopril-mediated regression of myocardial fibrosis. Hypertension. 28:1996;269-275.
139. Díez J., Querejeta R., López B., et al. Losartan-dependent regression of myocardial fibrosis is associated with reduction of left ventricular chamber stiffness in hypertensive patients. Circulation. 105:2002;2512-2517.
140. Anversa P., Kajstura J., Olivetti P. Myocyte death in heart failure. Curr Opin Cardiol. 11:1996;245-251.
141. 1 (I) collagen mRNA into myocardium from the spontaneously hypertensive rat during the transition from compensated hypertrophy to failure. J Mol Cell Cardiol. 29:1997;2335-2344.
142. Anversa P., Leri A., Beltrami C.A., Guerra S., Kajstura J. Myocyte death and growth in the failing heart. Lab Invest. 78:1998;767-786.
143. Anversa P., Ricci R., Olivetti G. Quantitative structural analysis of the myocardium during physiologic growth and induced cardiac hypertrophy: a review. J Am Coll Cardiol. 7:1986;1140-1149.
144. Grossman W., Carabello B.A., Gunther S., Pfeffer M.A. Ventricular wall stress and the development of cardiac hypertrophy and failure. Alpert N.R. Perspectives in cardiovascular research: myocardial hypertrophy and failure. 1993;1-18 Raven Press, New York.
145. Anversa P., Zhang X., Li P., Capasso J.M. Chronic coronary artery constriction leads to moderate myocyte loss and left ventricular dysfunction and failure in rats. J Clin Invest. 89:1992;618-629.
146. Neubauer S. High-energy phosphate metabolism in normal, hypertrophied and failing human myocardium. Heart Fail Rev. 4:1999;269-280.
147. Lamb H.J., beyerbracht H.P., van der Laarse A., et al. Diastolic function in hypertensive heart disease is associated with altered myocardial metabolism. Circulation. 99:1999;2261-2267.
148. de las Fuentes L., Herrero P., Peterson L.R., et al. Myocardial fatty acid metabolism. Independent predictor of left ventricular mass in hypertensive heart disease. Hypertension. 41:2003;83-87.
149. 31P-SLOOP magnetic resonance spectroscopy. J Am Coll Cardiol. 40:2002;1267-1274.
150. Lesnefsky E.J., Tandler B., Ye J., et al. Myocardial ischemia decreases oxidative phosphorylation through cytochrome oxidase in subsarcolemmal mitochondria. Am J Physiol. 273:1997;H1544-H1554.
151. Nerheim P., Krishnan S.C., Olshansky B., Shivkumar K. Apoptosis in the genesis of cardiac rhythm disorders. Cardiol Clin. 19:2001;155-163.
152. Moncrief J., McGavigan A.D., Dunn F.G. Arrhythmias, sudden death and syncope in hypertensive cardiovascular disease. Card Electrophysiol Rev. 6:2002;36-41.
153. Kanoh M., Takemura G., Misao J., et al. Significance of myocytes with positive DNA in situ nick end-labeling (TUNEL) in hearts with dilated cardiomyopathy: not apoptosis but DNA repair. Circulation. 99:1999;2757-2764.
154. Ohno M., Takemura G., Ohno A., et al. 'Apoptotic' myocytes in infarct area in rabbit hearts may be oncotic myocytes with DNA fragmentation: analysis with immunogold electron microscopy combined with in situ nick end labeling. Circulation. 98:1998;1422-1430.
155. Didenko V.V., Hornsby P.J. Presence of double-strand breaks with single-base 3′ overhangs in cells undergoing apoptosis but not necrosis. J Cell Biol. 135:1996;1369-1376.
156. Didenko V.V., Tunstead J.R., Hornsby P.J. Biotin-labeled hairpin oligonucleotides: probes to detect double-strand breaks in DNA in apoptotic cells. Am J Pathol. 152:1998;897-902.
157. Saraste A., Pulkki K. Morphologic and biochemical hallmarks of apoptosis. Cardiovasc Res. 45:2000;528-537.
158. Fadok V.A., Voelker D.R., Campbell P.A., et al. Exposure of phosphatidylserine on the surface of apoptotic lymphocytes triggers specific recognition and removal by macrophages. J Immunol. 148:1992;2207-2216.
159. Verhoven B., Schlegel R.A., Williamson P. Mechanisms of phosphatidylserine exposure, a phagocyte recognition signal, on apoptotic T lymphocytes. J Exp Med. 182:1995;1597-1601.
160. 2+-bridging mechanism and phospholipid head group recognition in the membrane-binding protein annexin V. Nat Struct Biol. 2:1995;968-974.
161. Reutelingsperger C.P.M., Dumont E., Thimister P.W., et al. Visualization of cell death in vivo with the annexin A5 imaging protocol. J Immunol Methods. 265:2002;123-132.
162. Flotats A., Carrió I. Non-invasive in vivo imaging of myocardial apoptosis and necrosis. Eur J Nucl Med. 30:2003;615-630.
163. Kaneko N., Matsuda R., Hosoda S., Kajita T., Ohta Y. Measurement of plasma annexin V by ELISA in the early detection of acute myocardial infarction. Clin Chim Acta. 251:1996;65-80.
164. Renz A., Burek C., Mier W., et al. Cytochrome c is rapidly extruded from apoptotic cells and detectable in serum of anticancer-drug treated tumor patients. Adv Exp Med Biol. 495:2001;331-334.
165. Strauss H.W., Narula J., Blankenberg F.G. Radioimaging to identify myocardial cell death and probably injury. Lancet. 356:2000;180-181.
166. Blankenberg F.G., Storrs R.W., Naumovski L., Goralski T., Spielman D. Detection of apoptotic cell death by proton nuclear magnetic resonance spectroscopy. Blood. 87:1996;1951-1956.
167. Blankenberg F., Narula J., Strauss H.W. In vivo detection of apoptotic cell death: a necessary measurement for evaluating therapy for myocarditis, ischemia, and heart failure. J Nucl Cardiol. 6:1999;531-539.
168. McMurray J., Pfeffer M.A. New therapeutic options in congestive heart failure. Part II. Circulation. 105:2002;2223-2228.
169. Chen Z., Siu B., Ho Y.S., et al. Overexpression of MnSOD protects against myocardial ischemia/reperfusion injury in transgenic mice. J Mol Cell Cardiol. 30:1998;2281-2289.
170. Oskarsson H.J., Coppey L., Weiss R.M., Li W.G. Antioxidants attenuate myocyte apoptosis in the remote non-infarcted myocardium following large myocardial infarction. Cardiovasc Res. 45:2000;679-687.
171. Yue T.L., Ma X.L., Wang X., et al. Possible involvement of stress-activated protein kinase signaling pathway and Fas receptor expression in prevention of ischemia/reperfusion-induced cardiomyocyte apoptosis by carvedilol. Circ Res. 82:1998;166-174.
172. Akao M., Ohler A., O'Rourke B., Marban E. Mitochondrial ATP-sensitive potassium channels inhibit apoptosis induced by oxidative stress in cardiac cells. Circ Res. 88:2001;1267-1275.
173. Akao M., Teshima Y., Marbán E. Antiapoptotic effect of nicorandil mediated by mitochondrial ATP-sensitive potassium channels in cultured cardiac myocytes. J Am Coll Cardiol. 40:2002;803-810.
174. Brocheriou V., Hagege A.A., Oubenaissa A., et al. Cardiac functional improvement by a human Bcl-2 transgene in a mouse model of ischemia/reperfusion injury. J Gene Med. 2:2000;326-333.
175. Guttenplan N., Lee C., Frishman W.H. Inhibition of myocardial apoptosis as a therapeutic target in cardiovascular disease prevention: focus on caspase inhibition. Heart Dis. 3:2001;313-318.
176. Brar B.K., Stephanou A., Liao Z., et al. Cardiotrophin-1 can protect cardiac myocytes from injury when added both prior to simulated ischaemia and at reoxygenation. Cardiovasc Res. 51:2001;265-274.
177. Zolk O., O'Brien R.J., Weyand M., Eschenhagen T. Augmented expression of cardiotrophin-1 in failing human hearts is accompanied by diminished glycoprotein 130 receptor protein abundance. Circulation. 106:2002;1442-1446.
178. Wang L., Ma W., Markovich R., Cheng J.W., Wang P.H. Regulation of cardiomyocyte apoptotic signaling by insulin-like growth factor I. Circ Res. 83:1998;516-522.
179. Andronico G., Mangano M.T., Nardi E., et al. Insulin-like growth factor 1 and sodium-lithium countertransport in essential hypertension and in hypertensive left ventricular hypertrophy. J Hypertens. 11:1993;1097-1101.
180. Díez J., Laviades C., Martínez E., et al. Insulin-like growth factor binding proteins in arterial hypertension. Relationship to left ventricular hypertrophy. J Hypertens. 13:1995;349-355.